← Back to patent-cliff list
Phosphocreatine
Tier C — Watch / tradePhosphocreatine
Università Vita-Salute San Raffaele
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Hypotension, Respiratory insufficiency, 呼吸急促, 心动过缓, Tachycardia, Heart failure, 心脏停搏, 意识障碍
Regional status
US
-
EU
Phase III
2024-10-08
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Phosphocreatine?
Approved indications include: Hypotension, Respiratory insufficiency, 呼吸急促, 心动过缓, Tachycardia, Heart failure, 心脏停搏, 意识障碍.
When does the Phosphocreatine patent expire?
No public expiry year is available for Phosphocreatine yet; this page updates once verified.
How do I get a quote for Phosphocreatine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01